Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial – JOURNAL OF THORACIC ONCOLOGY

Reck, M; Barlesi, F; Yang, JCH; Westeel, V; Felip, E; Özgüroglu, M; Dols, MC; Sullivan, R; Kowalski, DM; Andric, Z; Lee, DH; Sezer, A; Hu, P; Wang, XZ; von Heydebreck, A; Jacob, N; Mehr, KT; Park, K – 2024 – 10.1016/j.jtho.2023.09.1445

Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial – LUNG CANCER

-Ares, LP; Goto, Y; Lim, DWT; Halmos, B; Cho, BC; Cobo, M; Larriba, JLG; Zhou, CC; Demedts, I; Atmaca, A; Baka, S; Mookerjee, B; Portella, S; Zhu, ZW; Wu, JC; Demanse, D; Dharan, B; Reck, M – 2024 – 10.1016/j.lungcan.2023.107451

Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer – JOURNAL FOR IMMUNOTHERAPY OF CANCER

Molina-Alejandre, M; Perea, F; Calvo, V; Martinez-Toledo, C; Nadal, E; Sierra-Rodero, B; Casarrubios, M; Casal-Rubio, J; Martinez-Martí, A; Insa, A; Massuti, B; Viteri, S; Aranda, IB; Rodriguez-Abreu, D; de Castro, J; Martínez, JM; Cobo, M; Wistuba, II; Parra, ER;...